XML 24 R15.htm IDEA: XBRL DOCUMENT v3.22.4
Intangibles
 6 Months Ended
Dec. 31, 2022
Text block [abstract]  
Intangibles
Note 10. Intangibles
 
    
Consolidated
  
    
December
2022
    
June 2022
Restated *
  
    
$
    
$
  
Paxalisib Licensing agreement - at acquired fair value
      16,407,788       16,407,788  
Less: Accumulated amortisation
      (6,708,555 )      (6,166,378 ) 
    
 
 
    
 
 
  
       9,699,233       10,241,410  
    
 
 
    
 
 
  
     
EVT-801 Licensing agreement - at cost
      9,813,362       9,813,362  
Less: Accumulated amortisation
      (1,308,448 )      (915,914 ) 
    
 
 
    
 
 
  
       8,504,914       8,897,448  
    
 
 
    
 
 
  
     
       18,204,147       19,138,858  
    
 
 
    
 
 
  
Reconciliations
Reconciliations of the written down values at the beginning and end of the current financial half-year are set out below:
 
    
EVT801
licensing
agreement
Restated*
    
Paxalisib
licensing
agreement
    
Total
  
Consolidated
   
$
    
$
    
$
  
Balance at 1 July 2022
      8,897,448       10,241,410       19,138,858  
Amortisation expense
      (392,534 )      (542,177 )      (934,711 ) 
    
 
 
    
 
 
    
 
 
  
       
Balance at 31 December 2022
      8,504,914       9,699,233       18,204,147